EA-230

Synthetic Tetrapeptide (cholesterol Conjugated)Rx: InvestigationalCompound: Investigational

Also known as: AQGV, cholesterol-AQGV, EA230

Educational Only — Not medical advice. Consult a qualified clinician before using any peptide.

Summary

EA-230 is an investigational cholesterol-conjugated tetrapeptide (AQGV) derived from hCG, developed primarily for the treatment of sepsis and acute kidney injury associated with systemic inflammatory states. It has been evaluated in Phase II clinical trials showing safety and potential efficacy in modulating the inflammatory response during cardiac surgery and sepsis.

Mechanism of Action

EA-230 is a synthetic linear tetrapeptide (AQGV) conjugated to cholesterol, derived from the beta subunit of human chorionic gonadotropin (hCG). It modulates the innate immune response by reducing systemic inflammation, attenuating pro-inflammatory cytokine release (including IL-6, TNF-alpha), and may activate anti-inflammatory signaling pathways. It has demonstrated organ-protective effects in models of sepsis and ischemia-reperfusion injury.

Routes of Administration

Intravenous

Goals & Uses

  • Reduction of pro-inflammatory cytokinesCytokine ModulationModerate
  • Attenuation of sepsis-associated systemic inflammationAnti Inflammatory / ImmunomodulationModerate
  • Organ protection in ischemia-reperfusion injuryOrgan ProtectionLow
  • Acute kidney injury prevention/treatmentNephroprotectionModerate

Contraindications

  • Known hypersensitivity to EA-230 or its componentsAllergyHigh

Adverse Effects

  • HeadacheNeurologicUncommonPain in the head or upper neck
  • HypotensionCardiovascularUnknownLow blood pressure
  • NauseaGastrointestinalUncommonFeeling of sickness or urge to vomit
  • Infusion site reactionsLocalUncommon

Drug Interactions

  • VasopressorsLow
  • ImmunosuppressantsModeratePotential interaction with immune pathways or infection risk

Population Constraints

  • Pediatric patientsAgeRelative
  • Pregnant womenReproductiveRelative
  • Severe hepatic impairmentOrgan ImpairmentRelative

Regulatory Status

  • European UnionInvestigationalPhase II trials conducted in EU (Netherlands); no EMA approval.
  • United StatesInvestigationalNo FDA approval; investigational status only.
  • United KingdomUnknownNo known MHRA approval or specific UK trial registration identified.

Not approved by FDA, EMA, or any major regulatory body. Developed by Exponential Biotherapies / Inflammatix. Phase II clinical trials conducted in the Netherlands and internationally. No approved indications as of last available data.

Evidence & Sources

No sources recorded yet.

Browse All PeptidesBuild My Stack